AR and prostate cancer: Our finding that TLE3 loss, in conjunction with AR inhibition, leads to GR upregulation provides deeper insight into the epigenetic regulation of the GR locus in prostate cancer cells and supports the previously undescribed role of TLE3 in conferring enzalutamide sensitivity via GR.